|
KRN5500 Demonstrated Significant Reduction in Pain and Superior Performance vs. Placebo
RALEIGH, NC, USA | November 23, 2009 | DARA BioSciences, Inc. (Nasdaq:DARA - News), a biopharmaceutical development company, presented clinical data results for KRN5500, its lead compound for Neuropathic Pain, which achieved its primary endpoint of pain reduction and demonstrated superior performance vs. Placebo (p=0.03). These study results were presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held November 19-21, 2009 in San Francisco.
Sharon M. Weinstein, MD, a leading investigator in the study, presented a poster entitled "KRN5500 Demonstrates Significant Reduction in Neuropathic Pain Intensity in Patients with Cancer." The presentation provided an overview of the results from the recently completed multicenter, placebo-controlled, blinded, randomized, parallel group study designed to evaluate the safety and efficacy of KRN5500 in patients with neuropathic pain and advanced cancer. In this study KRN5500 demonstrated clinical proof of concept by meeting the primary efficacy endpoint of pain reduction.
Dr. Weinstein is a physician at the University of Utah and Huntsman Cancer Institute in Salt Lake City, UT, and is a Fellow in the American Academy of Hospice and Palliative Medicine (FAAHPM).
"Chemotherapy-induced neuropathic pain occurs in approximately 40% of patients treated with polychemotherapy and often responds poorly to presently available pain medications. Based on these positive results, DARA plans to commence a Phase 2b study in 2010," said Linda Jett, MSN, RN, leader of the pain program at the Company.
"With two drug candidates in the clinic and collaboration with America Stem Cell, DARA is poised for an exciting and productive 2010," said Richard Franco, CEO.
Additional information about the conference can be found at http://www.neuropathicpain.org/.
About DARA BioSciences, Inc.
DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.
SOURCE: DARA BioSciences, Inc. |
